DENTSPLY SIRONA Confirms Non-Emerging Growth Status in 8-K

TL;DR

**DENTSPLY SIRONA filed an 8-K confirming it's not an emerging growth company, meaning full SEC reporting.**

AI Summary

DENTSPLY SIRONA Inc. filed an 8-K on January 9, 2024, primarily to disclose that it is not an emerging growth company. This filing, under Items 2.02, 7.01, and 9.01, indicates the company is a well-established entity, trading on The Nasdaq Stock Market LLC under the symbol XRAY. For investors, this means DENTSPLY SIRONA is subject to full public company reporting requirements, offering more transparency than an emerging growth company, which can be a positive for due diligence.

Why It Matters

This filing clarifies DENTSPLY SIRONA's regulatory status, confirming it is a mature company subject to standard SEC reporting, which can reassure investors seeking established businesses.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of regulatory status and does not indicate any new financial or operational risks.

Analyst Insight

A smart investor would note this filing as a confirmation of DENTSPLY SIRONA's established status, implying greater regulatory scrutiny and transparency compared to an emerging growth company, which can be factored into their due diligence process.

Key Numbers

• $0.01 — Par value per share (The stated par value of DENTSPLY SIRONA's common stock.)

Key Players & Entities

• DENTSPLY SIRONA Inc. (company) — the registrant filing the 8-K
• The Nasdaq Stock Market LLC (company) — the exchange where DENTSPLY SIRONA's common stock is registered
• XRAY (company) — trading symbol for DENTSPLY SIRONA Inc.
• January 9, 2024 (date) — date of the earliest event reported and filing date
• $0.01 (dollar_amount) — par value per share of common stock

Forward-Looking Statements

• DENTSPLY SIRONA will continue to be subject to full SEC reporting requirements. (DENTSPLY SIRONA Inc.) — high confidence, target: Ongoing

FAQ

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share XRAY The Nasdaq Stock Market
• $3.90 billion — ts previously provided outlook range of $3.90 billion to $3.94 billion and reaffirms prelimin
• $3.94 billion — vided outlook range of $3.90 billion to $3.94 billion and reaffirms preliminary expectations
• $1.80 — per share ("EPS") to be in the range of $1.80 to $1.85. The Company further expects t
• $1.85 — ("EPS") to be in the range of $1.80 to $1.85. The Company further expects to report

Filing Documents

• xray-20240109.htm (8-K) — 31KB
• ex991-01092024preliminar.htm (EX-99.1) — 8KB
• ex992-01102024xrayjpmhea.htm (EX-99.2) — 20KB
• ex991-01092024preliminar001.jpg (GRAPHIC) — 236KB
• ex991-01092024preliminar002.jpg (GRAPHIC) — 40KB
• ex991-01092024preliminar003.jpg (GRAPHIC) — 230KB
• ex992-01102024xrayjpmhea001.jpg (GRAPHIC) — 77KB
• ex992-01102024xrayjpmhea002.jpg (GRAPHIC) — 249KB
• ex992-01102024xrayjpmhea003.jpg (GRAPHIC) — 112KB
• ex992-01102024xrayjpmhea004.jpg (GRAPHIC) — 96KB
• ex992-01102024xrayjpmhea005.jpg (GRAPHIC) — 117KB
• ex992-01102024xrayjpmhea006.jpg (GRAPHIC) — 109KB
• ex992-01102024xrayjpmhea007.jpg (GRAPHIC) — 80KB
• ex992-01102024xrayjpmhea008.jpg (GRAPHIC) — 89KB
• ex992-01102024xrayjpmhea009.jpg (GRAPHIC) — 113KB
• ex992-01102024xrayjpmhea010.jpg (GRAPHIC) — 118KB
• ex992-01102024xrayjpmhea011.jpg (GRAPHIC) — 42KB
• ex992-01102024xrayjpmhea012.jpg (GRAPHIC) — 219KB
• ex992-01102024xrayjpmhea013.jpg (GRAPHIC) — 42KB
• 0000818479-24-000004.txt ( ) — 2910KB
• xray-20240109.xsd (EX-101.SCH) — 2KB
• xray-20240109_lab.xml (EX-101.LAB) — 24KB
• xray-20240109_pre.xml (EX-101.PRE) — 13KB
• xray-20240109_htm.xml (XML) — 3KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition DENTSPLY SIRONA Inc. (the "Company") is providing preliminary unaudited selected results for the full year 2023 to facilitate the Company's participation in the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 (the "Conference"). Based on preliminary financial information, the Company anticipates its estimated net sales for the year ended December 31, 2023 will be at or above the high end of its previously provided outlook range of $3.90 billion to $3.94 billion and reaffirms preliminary expectations for adjusted earnings per share ("EPS") to be in the range of $1.80 to $1.85. The Company further expects to report year-over-year sales growth in its Essential Dental Solutions, Wellspect Healthcare, and Orthodontic and Implant Solutions segments, partially offset by declines in its Connected Technology Solutions segment. The Company also reaffirms its expectations for double-digit adjusted EPS growth in 2024. The Company does not provide forward-looking or preliminary estimates of adjusted EPS on a GAAP basis as certain information needed to prepare adjustments is not yet available and cannot be reasonably estimated. A description of the adjustments typically made to compute adjusted EPS can be found in Exhibit 99.1 to the Company's Current Report on Form 8-K filed on November 2, 2023. The preliminary 2023 estimates for net sales and adjusted EPS are based on management's preliminary assessment of operations for the year ended December 31, 2023. The Company expects to issue full financial results for the fourth quarter and fiscal year 2023 on or around February 29, 2024. This presentation is unaudited and preliminary and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2023. The presentation is being announced by a widely disseminated press release and will be made available to the public by webcast. A copy of the Compa

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure During the Conference, representatives of the Company will present the materials attached as Exhibit 99.2. A copy of the presentation is being furnished as Exhibit 99.2 to this report. The information furnished pursuant to Item 2.02 and Item 7.01 in this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits: 99.1 DENTSPLY SIRONA Inc. Press Release Issued January 9, 2024 99.2 DENTSPLY SIRONA Inc. J.P. Morgan Conference Presentation, dated January 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)

Forward-Looking Statements

Forward-Looking Statements All statements in this Current Report on Form 8-K that do not directly and exclusively relate to historical facts constitute "forward-looking statements." These statements represent current expectations and beliefs and no assurance can be given that the results described in such statements will be achieved. Such statements are subject to numerous assumptions, risks, uncertainties and other factors, including those described in the section titled "Risk Factors" in Dentsply Sirona's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as amended, and in other documents that we file with the Securities and Exchange Commission. No assurance can be given that any expectation, belief, goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. The Company does not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this Current Report on Form 8-K or to reflect the occurrence of unanticipated events. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DENTSPLY SIRONA Inc. By: /s/ Richard C. Rosenzweig Richard C. Rosenzweig Senior Vice President, Corporate Development, General Counsel and Secretary Date: January 9, 2024

View Full Filing

View this 8-K filing on SEC EDGAR